"I often wonder if they will ever look back at the ability to attack fibrosis in other organs after the dust settles with our current trials."
This is from a year ago so maybe...
"As the Company continues to prioritize its oncology objectives for 2025, we look forward to establishing the right partnership to further the clinical development pathway for leronlimab in the treatment of fibrosis of the liver and potentially other organs, such as the lungs and heart.”
https://www.cytodyn.com/investors/news-events...ignificant